.elizabeth loder, md, professor of neurology, harvard medical school; chief, division of headache, brigham & women's hospital..
loder, who hasn't been involved with any cgrp drug studies, cautions that these medicines don't work for everybody. and they may be risky for some people..
in a news release, the drug's manufacturer, amgen, said the list price will be 5 a month or ,900 annually. costs to patients may vary depending on insurance..
august 29, 2017.
.